Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
0.6873
-0.0090 (-1.29%)
At close: Oct 8, 2025, 4:00 PM EDT
0.6900
+0.0027 (0.39%)
After-hours: Oct 8, 2025, 7:17 PM EDT
Enveric Biosciences Employees
As of December 31, 2024, Enveric Biosciences had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,657,138
Market Cap
2.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -1 | -14.29% |
| Dec 31, 2023 | 7 | -19 | -73.08% |
| Dec 31, 2022 | 26 | 2 | 8.33% |
| Dec 31, 2021 | 24 | 21 | 700.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENVB News
- 6 days ago - Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials - Business Wire
- 20 days ago - Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds - Business Wire
- 21 days ago - Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds - Business Wire
- 21 days ago - Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery - Business Wire
- 22 days ago - Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission - Business Wire
- 5 weeks ago - Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 5 weeks ago - Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA - Business Wire
- 5 weeks ago - Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications - Business Wire